NCT02806050View on ClinicalTrials.gov

Palbociclib and FES PET

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 16, 2016

Primary Completion Date

September 28, 2022

Study Completion Date

September 28, 2022

Conditions
Breast Cancer
Interventions
DRUG

Palbociclib

all patients will be treated with palbociclib, on a 3 weeks on, 1 week off cycle until progression

DEVICE

FES PET

all patients will have a FES PET at baseline

DRUG

Letrozole

all patients will be treated with Letrozole daily until progression

Trial Locations (1)

9713 GZ

University Medical Center Groningen, Groningen

All Listed Sponsors
lead

University Medical Center Groningen

OTHER

NCT02806050 - Palbociclib and FES PET | Biotech Hunter | Biotech Hunter